Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans. / Lehrskov, Louise L; Kjeldsen, Sasha; Lyngbæk, Mark P; Chirstensen, Regitse Højgaard; Wedell-Neergaard, Anne-Sophie; Søderlund, Line; Jørgensen, Niklas Rye; Krogh-Madsen, Rikke; Wewer Albrechtsen, Nicolai J; Ellingsgaard, Helga.
I: Endocrine Research, Bind 4, Nr. 9, bvaa093, 2020.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Interleukin-6 May Not Affect Bone Resorption Marker CTX or Bone Formation Marker P1NP in Humans
AU - Lehrskov, Louise L
AU - Kjeldsen, Sasha
AU - Lyngbæk, Mark P
AU - Chirstensen, Regitse Højgaard
AU - Wedell-Neergaard, Anne-Sophie
AU - Søderlund, Line
AU - Jørgensen, Niklas Rye
AU - Krogh-Madsen, Rikke
AU - Wewer Albrechtsen, Nicolai J
AU - Ellingsgaard, Helga
N1 - © Endocrine Society 2020.
PY - 2020
Y1 - 2020
N2 - Context: Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited.Objective: To investigate if IL-6 regulates bone remodeling in humans.Design: Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies.Participants: Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3.Interventions: Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6.Main outcomes measures: Effect of IL-6 on CTX levels.Results: CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3).Conclusions: IL-6 may not regulate bone remodeling in humans.
AB - Context: Interleukin 6 (IL-6) contributes to bone remodeling in preclinical studies. Clinical trials investigating the role of IL-6 in bone remodeling are limited.Objective: To investigate if IL-6 regulates bone remodeling in humans.Design: Plasma concentrations of the bone resorption marker carboxy-terminal type I collagen crosslinks (CTX) and of the bone formation marker procollagen type 1 N-terminal propeptide (P1NP) were measured during a mixed-meal tolerance test (MMTT) in 3 placebo-controlled human studies.Participants: Five healthy individuals participated in study 1; 52 obese individuals, in study 2; and 10 healthy individuals, in study 3.Interventions: Study 1 was a single-blinded crossover study consisting of a 1-h infusion of saline (placebo) or the IL-6 receptor antibody tocilizumab followed by an exercise bout. Study 2 was a randomized, double-blinded 12-week exercise training intervention study. Participants received infusions of saline or tocilizumab. Study 3 was a randomized, double-blinded, crossover study consisting of 30 min infusion of saline or IL-6.Main outcomes measures: Effect of IL-6 on CTX levels.Results: CTX was significantly (P < 0.01) decreased during MMTTs in all 3 studies. Treatment with tocilizumab did not affect exercise or meal induced changes in plasma CTX or P1NP concentrations acutely (study 1) or after a 12-week treatment period (study 2). Exogenous IL-6 had no effect on CTX or P1NP plasma concentrations (study 3).Conclusions: IL-6 may not regulate bone remodeling in humans.
U2 - 10.1210/jendso/bvaa093
DO - 10.1210/jendso/bvaa093
M3 - Journal article
C2 - 32793846
VL - 4
JO - Endocrine Research Communications
JF - Endocrine Research Communications
SN - 0743-5800
IS - 9
M1 - bvaa093
ER -
ID: 250551394